Argo Biopharma is a clinical-stage biotechnology company committed to developing next-generation siRNA therapies to provide better treatment options for patients worldwide. We have a robust and diverse pipeline of RNAi drug candidates targeting a broad range of indications and are advancing six therapeutic candidates in the clinic. We leverage the power of collaboration to bolster our innovation engine to deliver best-in-class siRNA therapeutics while building top-tier clinical capabilities across multiple geographies.
Learn MoreOur industry-leading siRNA platform, RADS™ (RNA molecules with superior Activity, Durability, and Safety), is the cornerstone of our innovation. Built on this platform, our therapies are designed to deliver meaningful impact, with the goal of just one injection per year in clinical practice for certain indications.
Learn MoreWe’re advancing a broad pipeline of siRNA therapies that includes a range of indications, such as cardiovascular diseases, rare diseases, CNS disorders, viral hepatitis, metabolic conditions, and more.
Learn MoreWe’re developing best-in-class therapeutic candidates with our RADS™ siRNA platform and engage in collaborations with partners who share our commitment to advancing RNA-based medicines for a range of indications.
Learn More
Argo Biopharma to Present Positive Phase I Results of siRNA Therapeutic BW-20805 for HAE at ACAAI 2025
Learn MoreArgo Biopharma Receives IND Approval from NMPA for Phase II Clinical Trial of siRNA Therapy, BW-40202, for the Treatment of PNH
Argo Biopharma Completes First Patient Dosing for Phase II Clinical Trial in Chronic Hepatitis B
Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases
为了更好的呈现效果，移动端请竖屏浏览
